Clinical Significance of Basal-like Breast Cancer in Chinese Women in Heilongjiang Province |
Liu, Ying
(Department of Oncology, Second Affiliated Hospital of Harbin Medical University)
Jiang, Qiu-Ying (Department of Oncology, Second Affiliated Hospital of Harbin Medical University) Xin, Tao (Department of Oncology, Second Affiliated Hospital of Harbin Medical University) Cai, Li (Department of Oncology, Affiliated Oncology Hospital of Harbin Medical University) Zhao, Chang-Hong (Department of Oncology, Affiliated Oncology Hospital of Harbin Medical University) |
1 | EmadA Rakha, SomaiaE Elsheikh, MuhammedA Aleskandarany, et al (2009). Triple-Negative Breast Cancer: Distinguishing between Basal and Non-basal Subtypes. Clin Cancer Res, 15, April1. |
2 | Foulkes WD, Stefansson IM, Chappuis PO, et al (2003). Germ line BRCA1 mutations and a basal epithelialphe-no type in breast cancer. J Natl Cancer Inst, 95, 1482-5. DOI ScienceOn |
3 | Goldhirsch A, Wood WC, Gelber RD, et al (2003). Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol, 21, 3357-65. DOI ScienceOn |
4 | Kobayashi S (2008). Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer, 15, 153-8. DOI |
5 | Lakhani SR, Reis-Filho JS, Fulford L, et al (2005). Prediction of BRCA1 status inpatients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res, 11, 5175-80. DOI |
6 | Livasy CA, Perou CM, Karaca G, et al (2007). Identification of a basal-like subtype of breast ductal carcinoma insitu. HumPathol, 38, 197-204. |
7 | Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression datasets. Proc Natl Acad Sci USA, 100, 8418-23. DOI |
8 | Sotiriou C, Neo SY, McShane LM, et al (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA, 100, 10393-8. DOI |
9 | Tan DS, Marchio C, Jones RL, et al (2008). Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat, 111, 27-44. DOI |
10 | Tischkowitz M, Brunet JS, Begin LR, et al (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 7, 134. DOI |
11 | Wang Y, Zhe H, Ding Z, Gao P, Zhang N, Li G (2012). Cancer stem cell marker Bmi-1 expression is associated with basallike phenotype and poor survival in breast cancer. World J Surg, 36, 1189-94. DOI |
12 | Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast CancerStudy. JAMA, 295, 2492-502. DOI ScienceOn |
13 | Xu Z, Liu H, Lv X, et al (2011). Knockdown of the Bmi-1 oncogene inhibits cell proliferation and induces cell apoptosis and is involved in the decrease of Akt phosphorylation in the human breast carcinoma cell line MCF-7. Oncol Rep, 25, 409-18. |
14 | Yamamoto Y, Ibusuki M, Nakano M, et al (2009). Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer, 16, 260-7. DOI |
15 | Arnes JB, Collett K, Akslen LA, et al (2008). Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology, 52, 370-80. DOI |
16 | Bidard FC, Conforti R, Boulet T, et al (2007).negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triplenegative' breast cancers. Ann Oncol, 18, 1285-6. DOI ScienceOn |
17 | Brady-West DC, McGrowder DA (2011). Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev, 12, 2139-43. |
18 | Cheang MC, Voduc D, Bajdik C, et al (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14, 1368-76. DOI |
19 | Chuthapisith S, Permsapaya W, Warnnissorn M, et al (2012). Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women. Asian Pac J Cancer Prev, 13, 459-62. DOI ScienceOn |
20 | Matos I, Dufloth R, Alvarenga M, er al (2005). p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch, 447, 688-94. DOI |
21 | Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74. DOI ScienceOn |
22 | Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumors. Nature, 406, 747-52. DOI ScienceOn |
23 | Rakha EA, El-Sayed ME, Green AR, et al (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32. DOI ScienceOn |
24 | Sasa M, Bando Y, Takahashi M, et al (2008). Screening for basal marker expression is necessary or decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol, 97, 30-4. DOI |
25 | Shipitsin M, Campbell LL, Argani P, et al (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell, 11, 259-73. DOI |
26 | Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. DOI ScienceOn |
![]() |